Merck Gardasil BLA a priority?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck is requesting a priority review for its human papillomavirus vaccine Gardasil (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant), submitted Dec. 1. If granted a priority review, a June 1, 2006 approval would allow Merck to launch the vaccine before the 2006 back-to-school immunization season. GlaxoSmithKline continues development of its HPV vaccine Cervarix, which it claims offers viral protection against multiple viral strains and in a wider age group than Gardasil (Pharmaceutical Approvals Monthly July 2005, p. 4). GSK said it plans to submit Cervarix in 2006...
You may also be interested in...
GSK Sees Cervarix Cross-Protection, Age Range As Key Points Of Differentiation
GlaxoSmithKline expects to highlight a broad age range and cross-protection against multiple viral strains to differentiate its human papilloma virus vaccine Cervarix from Merck’s competing vaccine Gardasil.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.